These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

753 related items for PubMed ID: 32134200

  • 1. Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.
    Zhang L, Bai L, Liu X, Liu Y, Li S, Liu J, Zhang S, Yang C, Ren X, Cheng Y.
    Thorac Cancer; 2020 May; 11(5):1170-1179. PubMed ID: 32134200
    [Abstract] [Full Text] [Related]

  • 2. Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).
    Vergnenegre A, Geier M, Guisier F, Lamy R, Comet B, Le Garff G, Do P, Janicot H, Morel H, Decroisette C, Andre M, Falchero L, Paleiron N, Monnet I, GFPC Team.
    Cancer Med; 2020 Jan; 9(2):432-439. PubMed ID: 31747137
    [Abstract] [Full Text] [Related]

  • 3. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y.
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [Abstract] [Full Text] [Related]

  • 4. Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
    Miyawaki T, Kenmotsu H, Mori K, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Harada H, Endo M, Ohde Y, Takahashi K, Takahashi T.
    Clin Lung Cancer; 2020 Sep; 21(5):e405-e414. PubMed ID: 32205040
    [Abstract] [Full Text] [Related]

  • 5. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
    Ishii H, Azuma K, Kawahara A, Kinoshita T, Matsuo N, Naito Y, Tokito T, Yamada K, Akiba J, Hoshino T.
    Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
    [Abstract] [Full Text] [Related]

  • 6. Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India.
    Kumar S, Joga S, Biswas B, Dabkara D, Prasad KT, Singh N, Malik PS, Khurana S, Ganguly S, Muthu V, Batra U.
    Curr Probl Cancer; 2020 Jun; 44(3):100549. PubMed ID: 32035693
    [Abstract] [Full Text] [Related]

  • 7. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence.
    Byeon S, Cho JH, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Cancer Med; 2020 Apr; 9(7):2352-2362. PubMed ID: 32027780
    [Abstract] [Full Text] [Related]

  • 8. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
    Chen M, Li Q, Xu Y, Zhao J, Zhang L, Wei L, Zhong W, Wang M.
    Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
    [Abstract] [Full Text] [Related]

  • 9. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K.
    JAMA Netw Open; 2023 Jul 03; 6(7):e2322915. PubMed ID: 37432682
    [Abstract] [Full Text] [Related]

  • 10. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Takamori S, Takada K, Shimokawa M, Jinnnouchi M, Matsubara T, Haratake N, Miura N, Toyozawa R, Yamaguchi M, Takenoyama M, Yoneshima Y, Tanaka K, Okamoto I, Tagawa T, Mori M.
    Cancer Immunol Immunother; 2021 Jun 03; 70(6):1745-1753. PubMed ID: 33389013
    [Abstract] [Full Text] [Related]

  • 11. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A, Rothschild SI, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Joerger M.
    Cancer Chemother Pharmacol; 2020 Jan 03; 85(1):121-131. PubMed ID: 31745593
    [Abstract] [Full Text] [Related]

  • 12. The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Oh MS, Guzner A, Wainwright DA, Mohindra NA, Chae YK, Behdad A, Villaflor VM.
    Clin Lung Cancer; 2021 Jan 03; 22(1):e57-e62. PubMed ID: 32900613
    [Abstract] [Full Text] [Related]

  • 13. Timing of resumption of immune checkpoint inhibitor therapy after successful control of immune-related adverse events in seven advanced non-small cell lung cancer patients.
    Kashiwabara K, Fujii S, Tsumura S, Sakamoto K.
    Anticancer Drugs; 2020 Sep 03; 31(8):872-875. PubMed ID: 32796406
    [Abstract] [Full Text] [Related]

  • 14. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, Cousin S, Duchemann B, le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Lechapt E, Planchard D, De Ruysscher D, Dingemans AM, Besse B.
    J Thorac Oncol; 2019 Jul 03; 14(7):1244-1254. PubMed ID: 30780002
    [Abstract] [Full Text] [Related]

  • 15. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
    Takamori S, Komiya T, Powell E.
    Cancer Med; 2021 Feb 03; 10(3):923-932. PubMed ID: 33340271
    [Abstract] [Full Text] [Related]

  • 16. Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities.
    Kikuchi R, Watanabe Y, Okuma T, Nakamura H, Abe S.
    Cancer Immunol Immunother; 2024 Sep 05; 73(11):211. PubMed ID: 39235641
    [Abstract] [Full Text] [Related]

  • 17. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
    Tambo Y, Sone T, Shibata K, Nishi K, Shirasaki H, Yoneda T, Araya T, Kase K, Nishikawa S, Kimura H, Kasahara K.
    Clin Lung Cancer; 2020 Sep 05; 21(5):e366-e379. PubMed ID: 32199806
    [Abstract] [Full Text] [Related]

  • 18. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X, Wang L, Chen S, Zhou F, Zhao J, Zhao W, Su C.
    Thorac Cancer; 2020 Oct 05; 11(10):2812-2819. PubMed ID: 32779372
    [Abstract] [Full Text] [Related]

  • 19. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.
    Wang S, Liang Q, Chi Y, Zhuo M, An T, Duan J, Wang Z, Wang Y, Zhong J, Yang X, Chen H, Wang J, Zhao J.
    Thorac Cancer; 2020 May 05; 11(5):1149-1159. PubMed ID: 32162417
    [Abstract] [Full Text] [Related]

  • 20. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
    Liang H, Xu Y, Chen M, Zhong W, Wang M, Zhao J.
    Thorac Cancer; 2020 Apr 05; 11(4):1068-1075. PubMed ID: 32129934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.